(Q37533556)

20 August 2017

1 reference

title

New antibiotics for the management of complicated skin and soft tissue infections: are they any better? (English)

1 reference

20 August 2017

Dilip Nathwani

1

1 reference

20 August 2017

publication date

1 July 2009

1 reference

International Journal of Antimicrobial Agents

20 August 2017

published in

1 reference

20 August 2017

volume

34 Suppl 1

1 reference

20 August 2017

page(s)

S24-9

1 reference

Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Current and novel antibiotics against resistant Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Antimicrobial resistance in Europe and its potential impact on empirical therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Antibiotic options for treating community-acquired MRSA.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

What's new and not so new on the antimicrobial horizon?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Currently available antimicrobial agents and their potential for use as monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Future directions with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Daptomycin: rationale and role in the management of skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Appropriate vs. inappropriate antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

Evolving problems with resistant pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970546-1

7 January 2021

10.1016/S0924-8579(09)70546-1

Identifiers

DOI

1 reference

20 August 2017

1 reference